Trials / Recruiting
RecruitingNCT05636579
Study to Assess Safety and Tolerability of Multiple Doses of EO2002
Phase 1, Multiple Dose, Open-Label Study to Assess the Safety and Tolerability of EO2002 Intracameral Injections With or Without Topical Ripasudil in the Treatment of Corneal Edema
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- Asociación para Evitar la Ceguera en México · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical study is to assess the safety of multiple intracameral injections of EO2002 with and without topical Ripasudil.
Conditions
- Corneal Edema
- Corneal Endothelial Dystrophy
- Endothelial Dysfunction
- Fuchs Dystrophy
- Fuchs' Endothelial Dystrophy
- Bullous Keratopathy
- Pseudophakic Bullous Keratopathy
- Corneal Edema Pseudophakic
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | EO2002 | Intracameral injection of magnetic human corneal endothelial cells (EO2002) |
| DRUG | Ripasudil | Daily use of Ripasudil drops |
Timeline
- Start date
- 2022-11-08
- Primary completion
- 2025-12-09
- Completion
- 2025-12-09
- First posted
- 2022-12-05
- Last updated
- 2025-12-08
Locations
1 site across 1 country: Mexico
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05636579. Inclusion in this directory is not an endorsement.